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BACKGROUND: Statins are widely used to prevent
cardiovascular disease (CVD). With advancing age,
the risks of statins might outweigh the potential
benefits. It is unclear which factors influence general
practitioners’ (GPs) advice to stop statins in oldest-
old patients.
OBJECTIVE: To investigate the influence of a history of
CVD, statin-related side effects, frailty and short life expec-
tancy, onGPs’ advice to stop statins in oldest-old patients.
Milly A. van der Ploeg and Sven Streit contributed equally to this work.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s11606-018-4795-x) contains supplementary
material, which is available to authorized users.
Received March 15, 2018
Revised August 29, 2018
Accepted November 15, 2018
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
12
45
40
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
DESIGN:We invited GPs to participate in this case-based
survey. GPs were presented with 8 case vignettes describ-
ing patients > 80 years using a statin, and asked whether
they would advise stopping statin treatment.
MAINMEASURES:Cases varied in history of CVD, statin-
related side effects and frailty, with andwithout shortened
life expectancy (< 1 year) in the context ofmetastatic, non-
curable cancer. Odds ratios adjusted for GP characteris-
tics (ORadj) were calculated for GPs’ advice to stop.
KEY RESULTS: Two thousand two hundred fifty GPs
from 30 countries participated (median response rate
36%). Overall, GPs advised stopping statin treatment in
46% (95%CI 45–47) of the case vignettes; with shortened
life expectancy, this proportion increased to 90% (95CI%
89–90). Advice to stop wasmore frequent in case vignettes
without CVD compared to those with CVD (ORadj 13.8,
95%CI 12.6–15.1), with side effects compared to without
ORadj 1.62 (95%CI 1.5–1.7) and with frailty (ORadj 4.1,
95%CI 3.8–4.4) compared to without. Shortened life ex-
pectancy increased advice to stop (ORadj 50.7, 95%CI
45.5–56.4) and was the strongest predictor for GP advice
to stop, ranging across countries from 30% (95%CI 19–
42) to 98% (95% CI 96–99).
CONCLUSIONS: The absence of CVD, the presence of
statin-related side effects, and frailty were all indepen-
dently associated with GPs’ advice to stop statins in pa-
tients aged > 80 years. Overall, and within all countries,
cancer-related short life expectancy was the strongest
independent predictor of GPs’ advice to stop statins.
KEY WORDS: hydroxymethylglutaryl-CoA reductase inhibitors;
cardiovascular diseases; drug therapy; palliative care; general
practitioners; clinical decision-making.
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INTRODUCTION
Cholesterol-lowering treatment with statins is an important
part of cardiovascular risk management. Statins are frequently
used in old age and continued to the end of life.1, 2 Statins can
reduce the risk of cardiovascular events in old age.3 However,
in case of life-limiting illness or multi-morbidity, the risk-to-
benefit ratio of preventive statin treatment might favour stop-
ping. Clarity and evidence about the point at which statin
treatment is no longer beneficial is currently lacking.
General practitioners (GPs) are frequently confronted with
the question ‘is statin treatment still appropriate for this older
patient’. The lack of information about the risk-to-benefit ratio
of preventive treatment for older patients makes it challenging
for GPs to advise on statin therapy.4, 5 Guidelines generally do
not include recommendations when to stop statin treatment
(other than in the presence of adverse events).6–9 Statins have
been identified as in need of evidence-based deprescribing
guidelines.10 Recent research on GP decision-making on pri-
mary prevention of cardiovascular disease (CVD) suggests
that, while some GPs follow guidelines regardless of patient
age, other GPs take into consideration patient factors including
comorbidities, frailty and estimated life expectancy.4 It is
unclear how patient factors influence GPs’ advice on when
to stop statin treatment in older patients.
In the present multi-national study, we investigated how pa-
tient characteristics (history of CVD, statin-related side effects,
frailty and short life expectancy) influence GPs’ advice on stop-
ping statins in patients over 80 years. We also investigated what
other factors GPs consider relevant for stopping statin treatment.
METHODS
Setting
We conducted a survey of GPs (also called primary care
provider) from 30 countries using 8 case vignettes. This
study used the same approach for recruiting GP partic-
ipants as the previous study conducted by this research
group, that is using 29 GPs (National Coordinators) to
coordinate recruitment and distribute the survey through
a national GP network (for more details, see the
BProcedure^ section).11 Additionally, we recruited a Na-
tional Coordinator for Belgium resulting in a total of 30
participating countries: Austria, Belgium, Bosnia and
Herzegovina, Brazil, Czech Republic, Denmark, Finland,
France, Germany, Greece, Hungary, Ireland, Israel, Italy,
Latvia, Luxembourg, Macedonia, the Netherlands, New
Zealand, Norway, Poland, Portugal, Romania, Slovenia,
Spain, Sweden, Switzerland, Turkey, Ukraine and the
UK.
Participants
The National Coordinators distributed the survey across their
educational or research networks of practicing GPs. We aimed
for at least 20 participants per country. The number of GPs
invited per network varied between 25 and 1100 GPs per
country, with a median of 150.
Inclusion criteria for GPs were (1) the participant confirmed
to be working as a GP and (2) the participant answered at least
one question of the survey.
Procedure
We used SurveyMonkey (www.surveymonkey.com, Palo Al-
to, CA, USA) to build the online survey (see Appendix 1). The
National Coordinators translated the survey from English to
their own language when necessary, making the survey avail-
able in 21 languages. In Israel and Finland, the National
Coordinators distributed an English survey.
National coordinators distributed the survey by email. In
Ukraine, where web access was limited, a paper survey was
distributed. All National Coordinators were asked to send a
first reminder after 2–3 weeks. Responses were collected
anonymously (and labelled with a unique country code) be-
tween November 24, 2016, and April 11, 2017.
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Questionnaire
Appendix 1 represents the complete English survey.
GP Characteristics. We collected basic characteristics of
participating GP and their practices including gender, years
of experience, location of practice, and estimated proportion of
patients aged over 80 years, and use of clinical practice
guideline when treating patients aged over 80 years with
statins (5-item Likert scale).
The Case Vignettes. The survey contained eight case
vignettes. Each vignette described a patient aged over
80 years of unspecified gender consulting his or her GP
for a routine follow-up. All vignettes described patients
using a statin, with a low-density lipoprotein (LDL)
level within the participants’ desired target range (not
spec i f i e d ) , and w i t h no h i s t o r y o f f am i l i a l
hypercholesterolemia.
To develop the case vignettes, we consulted 10 prac-
tising GPs from our network of regional practices and
asked them to list their most important reasons for
stopping statin treatment in patients aged over 80 years.
We selected the four most frequent reasons for use in
the survey vignettes: absence of history of CVD, statin-
related side effect, frailty, and short life expectancy. For
each vignette, participating GPs were asked if they
would advise stopping statin treatment. Participating
GPs were also asked if they would advise stopping
statin treatment for each vignette if the patient addition-
ally had a life expectancy of < 1 year due to a diagnosis
of metastatic, non-curable cancer. Since predicting the
prognosis of a patient can be difficult, the reason for
limited life expectancy was added.
Characteristics of the Patients in the Case Vignette. History
of CVD. Each case vignette included the medical history of the
patient. It was explicitly stated whether CVD was present or not.
Statin-Related Side Effects. If present, the case vignette
included the statement: ‘has complaints of myalgia, which is
possibly a statin related side effect’. In the 4 case vignettes
including statin-related side effects (case 2, 4, 6 and 8), GPs
could choose to (a) stop statin treatment, (b) continue the same
statin or (c) lower the current dose or switch to another type of
statin. In further analyses, we dichotomized to ‘advise to stop
statin’ (answer a) and ‘advise not to stop statin’ (answers b + c).
Frailty. Because frailty lacks a clear definition,12 we used the
frailty definition by Fried et al. (2001),13 that is, unintentional
weight loss, exhaustion, low level of activity, muscle weakness
and slow gait speed. For each case vignette, we indicated one of
the following statements: ‘You consider this patient to be frail’
or ‘You don’t consider this patient to be frail’.
To avoid order bias, the 8 cases were presented to partici-
pating GPs in a random order.
Other Reasons for Stopping
We also asked participating GPs what factors they considered
when stopping statin treatment in patients aged over 80 years,
and which factor they considered most important.
Statistical Analyses
We calculated proportions to describe categorised baseline
data. For each of the case vignettes, we calculated proportions
and 95%CIs for participants advising stopping statin treatment
and the difference in proportions after adding short life expec-
tancy to the case vignettes.
We calculated ORs and 95%CIs for advice to stop
statin treatment using mixed-effect logistic regression
models accounting for clustering within GPs and coun-
tries (adjusted in the model as random-effects factors).
We performed crude and multivariable analyses, includ-
ing the 4 patient characteristics, where we a priori chose
to adjust for the GP characteristics (gender, years of
experience [< 5; 5–20; > 20], location of practice [city,
suburban, rural], estimated proportion of patients aged >
80 years [< 5; 5–20; > 20], and self-reported use of
guidelines [mainly yes; neutral; mainly no]). We per-
formed two sensitivity analyses of the multivariate mod-
el restricted to countries with a > 60% response rate
(n = 7) to assess selection bias and restricted to countries
where study team members were fluent in language to
control for correct translations (n = 14).
To investigate international variation, we calculated the
percentage of case vignettes with short life expectancy that
GPs advised stopping statins and the ORs for the strongest
independent predictor (short life expectancy) per country.
Again mixed-effect logistic regression techniques were used
including the 4 patient characteristics as fixed effects and GPs
as random effects.
A two-sided p value below 0.05 was considered statistically
significant.
Analyses were performed with SPSS version 22.0 (SPSS
Inc., Chicago, Ill., USA) and with STATA 15.0 (StataCorp,
College Station, TX, USA).
Data Availability. The datasets used and/or analysed during
the current study are available from the corresponding author
on reasonable request.
RESULTS
GP Characteristics
The survey was sent to a total of 10,048 GPs across 30
countries. The median response rate was 36% (range 7 to
93%) per country. Most responding GPs were from Switzer-
land (n = 497) and least from Greece (n = 15). Inclusion
criteria were met by 2250 (95%) of the 2362 responders.
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Table 1 presents the characteristics of the participating GPs:
54% were female, 50% practiced in a city, and 38% had >
20 years of experience working as a GP. Twenty-three percent
of GPs estimated that more than 20% of their practice popu-
lation were over 80 years.
Case Vignettes
Table 2 shows the percentages of GPs advising stopping statin
treatment for each case vignette with and without cancer-
related short life expectancy. The number of completed case
vignettes ranged between 1797 and 1806 with a mean of n =
1800.
Overall, 46% (95%CI 45–47) of GPs advised stopping
statin treatment in case vignettes without short life expectancy
(range across cases 5 to 82%). In cases with short life expec-
tancy, 90% of GPs advised stopping statins (95%CI 89–90)
(range across case vignettes 77 to 95%).
In case vignette 1, describing a non-frail 82-year-old patient
without CVD and without statin-related side effects, 50%
(95%CI 48–53) of GPs advised stopping statin treatment; this
increased to 91% GPs (95%CI 90–92) with added short life
expectancy.
In case vignette 5, describing a patient with CVD but
without statin-related side effects or frailty, only 5% of GPs
(95%CI 4–6) advised stopping statin treatment. However,
when short life expectancy was added, this increased to 76%
of GPs advising stopping statin treatment (95%CI 74–78).
Participants were most likely to advise stopping statin treat-
ment in case vignettes 3 and 4.
Table 3 shows ORs from the logistic regression model
testing the association of patient characteristics and GPs’
advice to stop statin treatment in patients aged over
80 years. Advice to stop statin treatment was more
frequent in case vignettes without CVD compared to
those with CVD (ORadj 13.8; 95%CI 12.6–15.1). Advice
to stop statin treatment was more frequent in case vi-
gnettes with statin-related side effects (ORadj 1.6; 95%CI
1.5–1.7); or with frailty (ORadj 4.1; 95%CI 3.8–4.4)
compared to those without these characteristics. Addi-
tion of short life expectancy in the context of metastatic,
non-curable cancer to the case vignettes increased advice
of stopping (ORadj 50.7; 95%CI 45.5–56.4) consider-
ably. The two sensitivity analyses yielded similar results
(data not shown). In case vignettes with statin-related
side effects and without CVD (case 2 and 4), most GPs
advised stopping statin treatment (62%; 95%CI 59–64
and 80%; 95%CI 78–82, respectively), but when statin-
related side effects occurred in cases with CVD (case 6
and 8), most GPs advised continuing statin treatment in
a lower dose or switching statin (74%; 95%CI 72–76
and 60%; 95%CI 57–62, respectively), rather than stop-
ping (17%; 95%CI 16–19 and 35%; 95%CI 33–37,
respectively).
Other Reasons to Stop Statin Treatment
Figure 1 shows the factors that GPs said they considered when
advising on stopping statin treatment in older patients. Partic-
ipant GPs considered short life expectancy of unspecified
cause the most important factor: 24% chose a life expectancy
< 3 months and 17% a life expectancy < 1 year. Other factors
GPs considered most important were patient preference
(16%), and myalgia (11%). About half of GPs (52%) selected
frailty as a reason to consider stopping statins, but only 3%
considered frailty the most important reason.
Twelve percent of the GPs suggested other reasons for
stopping including intolerance for the drug, hepatotoxicity
and primary prevention.
Table 1 Characteristics of Participating GPs (n = 2250) from 30
Countries
GPs’ characteristics n (%)
Female GP 1211 (54)
Practice location
City 1134 (50)
Suburban 533 (24)
Rural 583 (26)
Experience as GP
< 5 years 358 (16)
5–20 years 1024 (46)
> 20 years 865 (38)
Self-estimated prevalence of patients over 80 years at own practice
≤ 20% 1697 (77)
> 20% 496 (23)
Treatment is based on (inter-)national guidelines
Mainly yes 835 (43)
Neutral 498 (26)
Mainly no 611 (31)
Table 2 Proportion GPs Advising to Stop Statins in Older Patients
with and Without Shortened Life Expectancy
Cases Case characteristics Proportion
of GPs
advising
stopping
statins
(patients
normal life
expectancy)
Proportion
of GPs
advising
stopping
statins
(patients
with short
life
expectancy‡)
CVD† Side
effects
Frailty % (95%CI) % (95%CI)
Overall 46 (45–47) 90 (89–91)
Case 1 – – – 50 (48–53) 91 (90–92)
Case 2 – + – 62 (59–64) 95 (93–96)
Case 3 – – + 82 (80–83) 95 (94–96)
Case 4 – + + 80 (78–82) 95 (95–97)
Case 5 + – – 5 (4–6) 77 (74–78)
Case 6 + + – 17 (16–19) 87 (85–89)
Case 7 + – + 35 (33–37) 86 (85–88)
Case 8 + + + 35 (33–37) 89 (87–90)
All case vignettes described one patient aged over 80 years of
unspecified gender who consulted their GPs for a routine control. All
patients already used statins, had an LDL level within the participants’
desired target range (not specified) and did not have a history of
familial hypercholesterolemia.
†CVD cardiovascular disease
‡Life expectancy < 1 year
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International Variation
The proportion of GPs advising stopping statin treatment in
case vignettes with a short life expectancy in the context of
metastatic non-curable cancer varied across countries, from
30% (95%CI 19–42) in Macedonia to 98% (95%CI 96–99) in
Belgium. Cancer-related short life expectancy was the stron-
gest independent predicator of GP advice to stop statin
treatment.
See Appendix 2 for the results per country.
DISCUSSION
In this international survey of more than 2200 GPs from 30
countries, we investigated how patient characteristics influ-
ence GP advice to stop statin treatment in patients 80 years and
over. Overall, in 46% of the case vignettes, GPs advised
stopping statin treatment (ranging across case vignettes from
5% to 82%). In case vignettes where life expectancy was <
1 year in the context of metastatic non-curable cancer, 90% of
GPs advised stopping statin treatment (range across case vi-
gnettes 77 to 95%). The absence of CVD, the presence of
statin-related side effects, and frailty were independently as-
sociated with GPs’ advice to stop statin treatment. There was
considerable international variation in GP advice to stop statin
treatment. Cancer-related short life expectancy was the stron-
gest independent predictor of GP advice to stop statins, overall
and across all countries.
Context of the Results
When cases included short life expectancy (< 1 year), 9 out of
10 GPs advised stopping statin treatment. Our study confirms
results from population-based studies showing that statin treat-
ment is more likely to be discontinued in older people in the
last year of life, independent of the need for primary or
secondary prevention of CVD.14, 15 The importance of con-
sidering stopping preventive medication in older people with
short life expectancy is increasingly recognised.16 We found
that statin-related life expectancy was the main reason for GPs
advising stopping statin treatment in patients aged over
Table 3 Association Between Patient Characteristics and GP Advice to Stop Statins in Patient > 80 Years
Characteristics Univariate Multivariate*
OR 95%CI P value ORadj 95%CI P value
No cardiovascular disease 4.6 4.3 to 4.8 < 0.01 13.8 12.6–15.1 < 0.01
Side effects 1.3 1.2 to 1.4 < 0.01 1.6 1.5–1.7 < 0.01
Frailty 2.1 2.0 to 2.2 < 0.01 4.1 3.8–4.4 < 0.01
Short life expectancy 17.6 16.3 to 19.0 < 0.01 50.7 45.5–56.4 < 0.01
*Adjusted for GP characteristics (gender, experience, location, prevalence of oldest-old, guideline compliance) and patient characteristics (frailty, side
effects, absence of cardiovascular disease and short life expectancy < 1 year). A mixed-effects model was used to account for multiple assessments of the
8 case vignettes per GP and per country
Figure 1 Reasons for GPs to stop statin treatment in patients over 80 years. The light grey coloured bars represent the proportion of GPs that
consider this reason to advise to stop statins in patients over 80 years (multiple reasons could be selected). The black coloured bars represent the
proportion of GPs that indicated this reason as the most important reason. Asterisk means life expectancy less than 3 months.
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80 years, consistent across countries. This study adds to the
ongoing discussion about appropriate prescribing in older
patients at the end of life reported in qualitative studies.4, 5, 7
Results of a recent trial suggest that stopping statin treatment
in patients with short life expectancy (mean age 74.1 (SD
11.6) years) might be safe and improve quality of life.17
Although short life expectancy was the strongest independent
predicator of GP advice to stop statin treatment in all countries,
the proportion of GPs advising stopping statin treatment var-
ied across countries. There are several possible explanations
for this variation. A previous study showed that18 high CVD
burden and low life expectancy at age 60 influences GPs
decision to start antihypertensive treatment. These country-
specific health characteristics could play a role in the decision
to advice to stop statin treatment as well. In addition, percep-
tions of the patient population about statin therapy across the
countries could play a role; these data were however not
available for all countries.
We also investigated the influence of CVD on GP advice to
stop statins in patients aged over 80 years. In cases with statin-
related side effects, when CVDwas present, most GPs advised
lowering the dose or switching the type of statin; but when
CVD was absent most GPs advised stopping the statin
(Table 3). This suggests that GPs believe statins have a lower
risk-to-benefit ratio for primary prevention than secondary
prevention in patients aged over 80 years. However, current
guidelines recommend treating patients with the maximum
tolerated dose or using a different type of statin, irrespective
of primary or secondary prevention.8, 19
While myalgia may be the main reason for statin discontin-
uation from a patient perspective, only 11% of GPs in our
study chose side effects as the most important reason for
stopping statins.20 The association between statin use and
myalgia is still debated.21, 22
Consistent with the international literature, we found that
GPs were more likely to advise stopping statin treatment when
frailty was present.4
Strengths and Limitations
This study has various strengths. First, this is the first interna-
tional study addressing this problem with a case-based study.
Second, we were able to include many respondents frommany
countries. Third, using case vignettes enabled us to investigate
the influence of patient characteristics on standardised cases,
which could not have been evaluated in a study based on real
patients. Forth, case vignettes were presented in random order
and clearly identified the factors to be considered when decid-
ing whether to stop statins. Fifth, we completed sensitivity
analyses for countries with a higher response rate (> 60%) and
languages where the study team was fluent to control for
correct translation returning similar results.
Our study has also some limitations. First, we used theoret-
ical case vignettes. It can be argued that our results do not fully
reflect daily practice and that social desirability bias and the
premise of the survey could have influenced our results and lead
to an overestimating of the willingness to stop statins. Although
using statins in oldest-old with frailty and limited life expectan-
cy is highly debated, we tried to use an as neutral as possible
language when presenting the case vignettes. Further, we are
confident that granting complete anonymity allowed GPs to
freely express. Second, most GPs were part of national educa-
tional or research networks and might not be representative for
all GPs. Third, we found some extremely high ORs (> 50)
suggesting some findings should be interpreted with caution.
Forth, we lost some respondents in the course of the survey.
From the initial 2,250 GPs, about 1,800 (80%) responded to all
questions of the survey. Given this proportion and by presenting
the case vignettes in random order, we believe that risk of a
selection bias is low. Fifth, we introduced the concept of limited
life expectancy in the context of cancer; thus, our results might
not be completely generalizable to the approach in patients with
other conditions (e.g. severe heart disease). However, our re-
spondents equally rated limited life expectancy (< 1 year) as the
second important reason to consider stopping statins also in a
general context not only limited to cancer (Fig. 1).
Implications
The high proportion of GPs advising stopping statin
treatment in patients with a cancer-related short life
expectancy stresses the need for more research and
clearer guidelines in this area. This dilemma—when to
(discuss to) stop preventive medication—is relevant in
any palliative care setting, independent of old age. How-
ever, in practice, it is difficult for doctors to accurately
predict patients’ life expectancy.23, 24 It is important that
the accuracy of such predictions are improved if they
are to guide the discontinuation of preventive medicines.
A topic for further research and guideline development is
the clarification of the risk-benefit profile of statins in older
people when used for primary and for secondary prevention,
given that GP advice to stop statins in the presence of statin-
related side effects varied depending on whether the statin was
being used for primary or secondary prevention.
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